Business

Driven by Tariffs, European Pharmaceutical Industry Pivots to the US

Analysts say drugmakers wouldn’t risk a disadvantage in the United States, the world’s biggest economy and pharmaceutical market.
Driven by Tariffs, European Pharmaceutical Industry Pivots to the US
A U.S. dollar note and pills in an illustration photo. Dado Ruvic/Reuters
Evgenia Filimianova
|Updated:
0:00

The U.S. tariff policy and its unmatched pharmaceutical market are pulling European drugmakers to invest more heavily, from new manufacturing plants to U.S. stock listings and discount pricing deals.

Since early 2025, European drugmakers have stepped up their U.S. presence. In the most recent move, UK pharmaceutical giant AstraZeneca announced on Sept. 29 a direct listing on the New York Stock Exchange, just months after pledging $50 billion of U.S. investment by 2030.
Evgenia Filimianova
Evgenia Filimianova
Author
Evgenia Filimianova is a UK-based journalist covering a wide range of international stories, with a particular interest in foreign policy, economy, and UK politics.